A Youssef, BK Mohammed, A Prasad… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction The recent discovery of TAK981 (Subasumstat), the first-in-class selective
inhibitor of SUMOylation, enables new immune treatments. TAK981 is already in clinical …